Latest news with #YKGI
Yahoo
2 days ago
- Business
- Yahoo
Asian Market Penny Stocks To Watch In July 2025
As global markets react positively to recent trade deals, with indices in the U.S. and Asia reaching new highs, investors are keenly observing the ripple effects across various sectors. Amidst this backdrop, penny stocks—often smaller or newer companies—continue to attract attention for their potential to offer unique growth opportunities. While traditionally seen as speculative, these stocks can present compelling investment cases when backed by robust financials and strategic positioning within their industries. Top 10 Penny Stocks In Asia Name Share Price Market Cap Financial Health Rating Food Moments (SET:FM) THB4.00 THB3.95B ★★★★★☆ YKGI (Catalist:YK9) SGD0.105 SGD44.62M ★★★★★★ Lever Style (SEHK:1346) HK$1.48 HK$933.81M ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.49 SGD198.59M ★★★★★☆ Goodbaby International Holdings (SEHK:1086) HK$1.14 HK$1.9B ★★★★★★ China Sunsine Chemical Holdings (SGX:QES) SGD0.725 SGD691.2M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.53 SGD9.96B ★★★★★☆ Beng Kuang Marine (SGX:BEZ) SGD0.25 SGD51.82M ★★★★★★ Livestock Improvement (NZSE:LIC) NZ$0.95 NZ$135.23M ★★★★★★ BRC Asia (SGX:BEC) SGD3.50 SGD960.23M ★★★★★★ Click here to see the full list of 971 stocks from our Asian Penny Stocks screener. Let's uncover some gems from our specialized screener. HuBei NengTer TechnologyLtd Simply Wall St Financial Health Rating: ★★★★★☆ Overview: HuBei NengTer Technology Co., Ltd operates an ecommerce platform focused on the supply chain of plastic raw materials in China, with a market cap of CN¥10.59 billion. Operations: No revenue segments have been reported for the company. Market Cap: CN¥10.59B HuBei NengTer Technology Ltd, with a market cap of CN¥10.59 billion, is currently pre-revenue and unprofitable. Despite this, it has a robust cash position with short-term assets exceeding both its short and long-term liabilities. The company has initiated a share buyback program worth up to CN¥50 million, which may indicate confidence in its valuation as it trades below estimated fair value. While earnings are forecasted to grow significantly at over 60% annually, the company faces challenges such as increasing debt levels and ongoing losses that have widened over the past five years. Click here to discover the nuances of HuBei NengTer TechnologyLtd with our detailed analytical financial health report. Gain insights into HuBei NengTer TechnologyLtd's outlook and expected performance with our report on the company's earnings estimates. Tianjin Chase Sun PharmaceuticalLtd Simply Wall St Financial Health Rating: ★★★★★★ Overview: Tianjin Chase Sun Pharmaceutical Co., Ltd is involved in the research, development, production, and sale of various pharmaceutical products both in China and internationally, with a market cap of CN¥12.62 billion. Operations: Revenue Segments: Not reported. Market Cap: CN¥12.62B Tianjin Chase Sun Pharmaceutical Ltd, with a market cap of CN¥12.62 billion, shows financial stability as its short-term assets exceed both short and long-term liabilities. The company has more cash than total debt, and its debt is well covered by operating cash flow. However, it faces challenges with declining earnings growth and reduced profit margins from 6.6% to 0.4% over the past year. Despite these setbacks, the stock trades at good relative value compared to peers and industry standards. Recent board changes may bring new strategic directions following their recent dividend affirmation for 2024 on A shares. Dive into the specifics of Tianjin Chase Sun PharmaceuticalLtd here with our thorough balance sheet health report. Explore Tianjin Chase Sun PharmaceuticalLtd's analyst forecasts in our growth report. Hunan Er-Kang Pharmaceutical Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Hunan Er-Kang Pharmaceutical Co., Ltd is engaged in the manufacturing and sale of active pharmaceutical ingredients, finished drug products, and pharmaceutical excipients both in China and internationally, with a market cap of CN¥8.79 billion. Operations: Hunan Er-Kang Pharmaceutical Co., Ltd has not reported any specific revenue segments. Market Cap: CN¥8.79B Hunan Er-Kang Pharmaceutical Co., Ltd, with a market cap of CN¥8.79 billion, is currently unprofitable and has seen losses increase by 25.9% annually over the past five years. The company's short-term assets of CN¥1.7 billion comfortably cover both its short-term liabilities of CN¥618.8 million and long-term liabilities of CN¥90.8 million, indicating financial stability in asset management despite profitability challenges. Its debt level is appropriate as cash holdings exceed total debt, but the stock remains highly volatile compared to other Chinese stocks, reflecting investor uncertainty amid its ongoing financial struggles and lack of significant revenue growth. Get an in-depth perspective on Hunan Er-Kang Pharmaceutical's performance by reading our balance sheet health report here. Learn about Hunan Er-Kang Pharmaceutical's historical performance here. Where To Now? Unlock more gems! Our Asian Penny Stocks screener has unearthed 968 more companies for you to here to unveil our expertly curated list of 971 Asian Penny Stocks. Seeking Other Investments? Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SZSE:002102 SZSE:300026 and SZSE:300267. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Asian Market Insights: Venus Medtech (Hangzhou) Among 3 Promising Penny Stocks
As global markets react to new trade agreements and economic data, the Asian market remains a focal point for investors seeking growth opportunities amidst evolving geopolitical landscapes. Penny stocks, often associated with smaller or newer companies, continue to attract attention for their potential to offer significant returns at lower entry points. Despite being considered a niche investment area today, these stocks can present compelling opportunities when backed by robust financial health and solid fundamentals. Top 10 Penny Stocks In Asia Name Share Price Market Cap Financial Health Rating Food Moments (SET:FM) THB4.00 THB3.95B ★★★★★☆ YKGI (Catalist:YK9) SGD0.105 SGD44.62M ★★★★★★ Lever Style (SEHK:1346) HK$1.48 HK$933.81M ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.49 SGD198.59M ★★★★★☆ Goodbaby International Holdings (SEHK:1086) HK$1.14 HK$1.9B ★★★★★★ China Sunsine Chemical Holdings (SGX:QES) SGD0.725 SGD691.2M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.53 SGD9.96B ★★★★★☆ Beng Kuang Marine (SGX:BEZ) SGD0.25 SGD51.82M ★★★★★★ Livestock Improvement (NZSE:LIC) NZ$0.95 NZ$135.23M ★★★★★★ BRC Asia (SGX:BEC) SGD3.50 SGD960.23M ★★★★★★ Click here to see the full list of 971 stocks from our Asian Penny Stocks screener. We're going to check out a few of the best picks from our screener tool. Venus Medtech (Hangzhou) Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Venus Medtech (Hangzhou) Inc. focuses on the research, development, manufacturing, and sale of bioprosthetic heart valves both in Mainland China and internationally, with a market cap of HK$1.32 billion. Operations: The company generates revenue primarily from its medical products segment, amounting to CN¥470.83 million. Market Cap: HK$1.32B Venus Medtech (Hangzhou) Inc. has a market cap of HK$1.32 billion and generates revenue of CN¥470.83 million from its medical products segment, but remains unprofitable with losses growing at 24.8% annually over five years. Despite this, the company maintains a strong cash position, covering both short and long-term liabilities with sufficient runway for more than three years based on current free cash flow levels. Recent board changes include the appointment of Mr. Ting Yuk Anthony Wu as chairman, reflecting potential strategic shifts as the company navigates its financial challenges amidst industry competition and growth opportunities in bioprosthetic heart valves. Get an in-depth perspective on Venus Medtech (Hangzhou)'s performance by reading our balance sheet health report here. Explore historical data to track Venus Medtech (Hangzhou)'s performance over time in our past results report. Town Health International Medical Group Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Town Health International Medical Group Limited is an investment holding company offering healthcare and related services in the People's Republic of China and Hong Kong, with a market cap of HK$1.79 billion. Operations: The company's revenue primarily comes from Hong Kong Medical Services (HK$829.68 million), the Hong Kong Managed Medical Network Business (HK$489.35 million), and Mainland Hospital Management and Medical Services (HK$546.62 million). Market Cap: HK$1.79B Town Health International Medical Group, with a market cap of HK$1.79 billion, derives significant revenue from its Hong Kong Medical Services (HK$829.68 million) and other healthcare segments, yet remains unprofitable. The company benefits from a stable cash position exceeding its total debt and short-term liabilities of HK$594.2 million, offering a cash runway exceeding three years due to positive free cash flow growth. Despite trading significantly below estimated fair value and having stable weekly volatility at 4%, challenges include increased debt-to-equity ratio over five years and an inexperienced management team averaging 1.3 years in tenure amidst ongoing financial losses. Click to explore a detailed breakdown of our findings in Town Health International Medical Group's financial health report. Assess Town Health International Medical Group's previous results with our detailed historical performance reports. Ratchthani Leasing Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Ratchthani Leasing Public Company Limited, along with its subsidiary, offers hire-purchase and leasing services in Thailand and has a market cap of THB10.47 billion. Operations: The company's revenue is primarily derived from its Financial Service Business, generating THB1.82 billion, and its Insurance Brokerage Business, contributing THB154.43 million. Market Cap: THB10.47B Ratchthani Leasing, with a market cap of THB10.47 billion, faces challenges as its earnings have declined by 14.6% annually over the past five years and experienced negative growth recently. Despite high net debt to equity at 222.9%, short-term assets comfortably cover both short- and long-term liabilities, indicating solid liquidity management. The company's operating cash flow effectively covers its debt obligations, though profitability remains pressured with a low return on equity of 5.2%. Recent board changes include Mr. Varavudh Varaporn's resignation due to health issues, impacting governance continuity amidst declining revenue and net income in early 2025 results. Click here and access our complete financial health analysis report to understand the dynamics of Ratchthani Leasing. Learn about Ratchthani Leasing's future growth trajectory here. Seize The Opportunity Reveal the 971 hidden gems among our Asian Penny Stocks screener with a single click here. Interested In Other Possibilities? AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:2500 SEHK:3886 and SET:THANI. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-07-2025
- Business
- Yahoo
Asian Penny Stocks Spotlight: HighTide Therapeutics And 2 Other Noteworthy Picks
As global markets continue to navigate a dynamic landscape, Asia's financial scene remains a focal point for investors seeking opportunities beyond traditional avenues. Penny stocks, despite their somewhat outdated terminology, still capture the interest of those looking to invest in smaller or newer companies with potential for growth. In this article, we spotlight several Asian penny stocks that exhibit strong financial health and could offer compelling opportunities for investors seeking stability and long-term potential. Name Share Price Market Cap Financial Health Rating YKGI (Catalist:YK9) SGD0.102 SGD43.35M ★★★★★★ Lever Style (SEHK:1346) HK$1.37 HK$864.4M ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$2.22 HK$1.85B ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.425 SGD172.25M ★★★★★☆ Goodbaby International Holdings (SEHK:1086) HK$1.13 HK$1.89B ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.21 SGD8.7B ★★★★★☆ Ekarat Engineering (SET:AKR) THB0.92 THB1.35B ★★★★★★ Beng Kuang Marine (SGX:BEZ) SGD0.225 SGD45.5M ★★★★★★ BRC Asia (SGX:BEC) SGD3.25 SGD891.64M ★★★★★★ United Energy Group (SEHK:467) HK$0.52 HK$13.44B ★★★★★★ Click here to see the full list of 987 stocks from our Asian Penny Stocks screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: HighTide Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for chronic metabolic and liver diseases in Mainland China, with a market cap of HK$1.70 billion. Operations: HighTide Therapeutics, Inc. does not report any specific revenue segments. Market Cap: HK$1.7B HighTide Therapeutics is a pre-revenue biopharmaceutical company with a market cap of HK$1.70 billion, focusing on chronic metabolic and liver diseases. Recent Phase 3 trials for HTD1801 showed promising results in treating type 2 diabetes mellitus, supporting plans to submit a new drug application in China. Despite having more cash than debt and sufficient short-term assets to cover liabilities, the company's share price remains highly volatile. The board's relative inexperience may be a concern, although the management team is seasoned. HighTide recently raised HK$124.99 million through an equity offering to support its development activities. Take a closer look at HighTide Therapeutics' potential here in our financial health report. Assess HighTide Therapeutics' previous results with our detailed historical performance reports. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Dongguan Rural Commercial Bank Co., Ltd. offers a range of banking products and services in China and has a market cap of HK$25.49 billion. Operations: Currently, there are no specific revenue segments reported for this company. Market Cap: HK$25.49B Dongguan Rural Commercial Bank, with a market cap of HK$25.49 billion, offers a mixed picture for investors interested in penny stocks. Recent earnings showed a decline in net income to CNY 1,633.18 million from the previous year, reflecting negative earnings growth of 15.5%. The bank's net profit margin decreased slightly to 51.3%, though it maintains high-quality earnings and an appropriate level of bad loans at 1.8%. Despite trading significantly below estimated fair value and having stable weekly volatility at 4%, the bank's return on equity remains low at 7.3%. The board is experienced with an average tenure of 5.6 years. Click here to discover the nuances of Dongguan Rural Commercial Bank with our detailed analytical financial health report. Gain insights into Dongguan Rural Commercial Bank's historical outcomes by reviewing our past performance report. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Greattown Holdings Ltd. operates in the real estate development sector in China, with a market capitalization of approximately CN¥7.22 billion. Operations: The company's revenue is primarily derived from its operations in China, totaling CN¥4.50 billion. Market Cap: CN¥7.22B Greattown Holdings Ltd., with a market cap of CN¥7.22 billion, presents a mixed outlook for penny stock investors in the real estate sector. The company reported first-quarter sales of CN¥674 million, marking significant improvement from the previous year, and achieved a net income of CN¥3.87 million after prior losses. Despite reducing its debt to equity ratio to 33.3% over five years, Greattown remains unprofitable with negative return on equity and insufficient cash flow coverage for debt. While short-term assets exceed liabilities significantly, earnings have declined annually by 52.8%, challenging its growth prospects amidst stable weekly volatility at 5%. Jump into the full analysis health report here for a deeper understanding of Greattown Holdings. Review our historical performance report to gain insights into Greattown Holdings' track record. Take a closer look at our Asian Penny Stocks list of 987 companies by clicking here. Ready To Venture Into Other Investment Styles? AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:2511 SEHK:9889 and SHSE:600094. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-07-2025
- Business
- Yahoo
Jiumaojiu International Holdings Leads The Charge In Asian Penny Stocks
Amid ongoing global economic shifts, Asian markets have been navigating the complexities of trade tensions and domestic policy adjustments. Penny stocks, while often considered a niche investment area, continue to capture attention due to their potential for growth in smaller or newer companies. By focusing on those with strong financial health and clear growth potential, investors can find opportunities among these stocks that might offer both stability and upside. Name Share Price Market Cap Financial Health Rating YKGI (Catalist:YK9) SGD0.102 SGD43.35M ★★★★★★ Lever Style (SEHK:1346) HK$1.37 HK$864.4M ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$2.25 HK$1.87B ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.44 SGD178.33M ★★★★★☆ Goodbaby International Holdings (SEHK:1086) HK$1.16 HK$1.94B ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.32 SGD9.13B ★★★★★☆ Ekarat Engineering (SET:AKR) THB0.92 THB1.35B ★★★★★★ Beng Kuang Marine (SGX:BEZ) SGD0.23 SGD46.51M ★★★★★★ BRC Asia (SGX:BEC) SGD3.33 SGD913.59M ★★★★★★ Bosideng International Holdings (SEHK:3998) HK$4.21 HK$48.33B ★★★★★★ Click here to see the full list of 983 stocks from our Asian Penny Stocks screener. Here we highlight a subset of our preferred stocks from the screener. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Jiumaojiu International Holdings Limited operates Chinese cuisine restaurant brands across several countries, including China, Singapore, Canada, Malaysia, the United States, Thailand and Indonesia with a market cap of HK$4.10 billion. Operations: The company's revenue is primarily derived from its restaurant brands, with Tai Er generating CN¥4.41 billion, Jiu Mao Jiu contributing CN¥546.18 million, and Song Hot Pot accounting for CN¥894.97 million. Market Cap: HK$4.1B Jiumaojiu International Holdings has shown mixed financial performance, with a reduction in profit margins from 7.6% to 0.9% over the past year, largely due to a significant one-off loss of CN¥142.5 million. Despite this, the company maintains a strong balance sheet with more cash than its total debt and short-term assets exceeding liabilities, indicating solid financial health. Recent announcements include a special dividend of HKD 0.02 per share for 2024, reflecting shareholder returns despite decreased profitability and negative earnings growth of -87.7%. The board is experienced; however, management's average tenure suggests new leadership dynamics. Unlock comprehensive insights into our analysis of Jiumaojiu International Holdings stock in this financial health report. Review our growth performance report to gain insights into Jiumaojiu International Holdings' future. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Zhewen Pictures Group Co., Ltd. operates in China by producing and selling yarns, with a market capitalization of CN¥4.51 billion. Operations: Revenue Segments: No specific revenue segments have been reported by the company. Market Cap: CN¥4.51B Zhewen Pictures Group Co., Ltd. has demonstrated encouraging financial metrics, with a significant reduction in its debt to equity ratio from 100.8% to 27.3% over five years and more cash than total debt, indicating robust financial management. The company's short-term assets of CN¥2.8 billion comfortably cover both short and long-term liabilities, reflecting strong liquidity. Despite recent earnings growth of 22%, this is below its impressive five-year average of 79.6%. Recent quarterly results show revenue rising to CN¥780.69 million from CN¥615.79 million year-on-year, with net income increasing modestly amidst stable profit margins and no meaningful shareholder dilution observed recently. Click to explore a detailed breakdown of our findings in Zhewen Pictures Groupltd's financial health report. Gain insights into Zhewen Pictures Groupltd's historical outcomes by reviewing our past performance report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Sanxiang Impression Co., Ltd. is involved in the development of real estate properties in China, with a market cap of CN¥4.33 billion. Operations: The company generates revenue of CN¥1.39 billion from its operations in China. Market Cap: CN¥4.33B Sanxiang Impression Co., Ltd. showcases solid financial stability with short-term assets of CN¥4.6 billion exceeding both its short and long-term liabilities, indicating strong liquidity. The company's recent earnings growth is substantial, with net income rising to CN¥15.58 million for the first quarter of 2025, reversing a previous loss. Despite a low return on equity at 0.4%, the firm's debt management is commendable, reducing its debt to equity ratio significantly over five years and maintaining satisfactory interest coverage at 10.1 times EBIT. However, the recent cancellation of an acquisition deal may impact strategic opportunities moving forward. Click here and access our complete financial health analysis report to understand the dynamics of Sanxiang Impression. Learn about Sanxiang Impression's historical performance here. Take a closer look at our Asian Penny Stocks list of 983 companies by clicking here. Seeking Other Investments? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 23 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:9922 SHSE:601599 and SZSE:000863. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
14-07-2025
- Business
- Yahoo
Asian Penny Stocks: 3 Picks Below US$2B Market Cap
Amidst a backdrop of muted market responses to new U.S. tariffs and mixed economic signals from major Asian economies, investors are increasingly looking towards smaller, less-established companies for potential growth opportunities. Penny stocks, often overlooked due to their association with higher risk, still represent a viable investment area when they possess strong balance sheets and solid fundamentals. In this article, we explore several penny stocks that may offer both stability and potential upside for those interested in tapping into the underappreciated segment of the market. Name Share Price Market Cap Financial Health Rating YKGI (Catalist:YK9) SGD0.102 SGD43.35M ★★★★★★ Lever Style (SEHK:1346) HK$1.37 HK$864.4M ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$2.25 HK$1.87B ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.44 SGD178.33M ★★★★★☆ Goodbaby International Holdings (SEHK:1086) HK$1.16 HK$1.94B ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.32 SGD9.13B ★★★★★☆ Ekarat Engineering (SET:AKR) THB0.92 THB1.35B ★★★★★★ Beng Kuang Marine (SGX:BEZ) SGD0.23 SGD46.51M ★★★★★★ BRC Asia (SGX:BEC) SGD3.33 SGD913.59M ★★★★★★ United Energy Group (SEHK:467) HK$0.53 HK$13.7B ★★★★★★ Click here to see the full list of 983 stocks from our Asian Penny Stocks screener. Let's explore several standout options from the results in the screener. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Beijing UBOX Online Technology Corp. operates vending machines in Mainland China and has a market cap of HK$2.91 billion. Operations: The company's revenue is primarily derived from its Unmanned Retail Business, which generated CN¥1.97 billion, followed by Merchandise Wholesale at CN¥552.82 million and Advertising and System Support Services at CN¥134.34 million. Market Cap: HK$2.91B Beijing UBOX Online Technology Corp., with a market cap of HK$2.91 billion, primarily generates revenue from its Unmanned Retail Business (CN¥1.97 billion). Despite being unprofitable, it has reduced losses by 11.3% annually over five years and maintains a stable cash runway exceeding three years due to more cash than debt. The management and board are experienced, with short-term assets covering liabilities effectively. However, the stock remains highly volatile with negative return on equity (-26.15%). Recent amendments to company bylaws suggest ongoing governance adjustments aligned with regulatory changes in China. Click here to discover the nuances of Beijing UBOX Online Technology with our detailed analytical financial health report. Gain insights into Beijing UBOX Online Technology's past trends and performance with our report on the company's historical track record. Simply Wall St Financial Health Rating: ★★★★★★ Overview: TradeGo FinTech Limited is an investment holding company that offers integrated securities trading platform services to brokerage firms and their clients in Hong Kong and the People's Republic of China, with a market cap of HK$689.95 million. Operations: The company's revenue is primarily derived from two segments: Financial Services with Operations Licensed Under The SFO, generating HK$69.12 million, and Market and Trading Integrated Terminal Products and System Services, contributing HK$73.13 million. Market Cap: HK$689.95M TradeGo FinTech Limited, with a market cap of HK$689.95 million, recently completed a follow-on equity offering raising HK$50.4 million. The company reported significant earnings growth for the year ending March 31, 2025, with sales reaching HK$129.7 million and net income at HK$63.95 million, driven partly by a large one-off gain of HK$12.3 million. Despite high volatility in its share price over the past three months and weekly volatility higher than most Hong Kong stocks, TradeGo benefits from being debt-free and having strong short-term asset coverage over liabilities (HK$200.6M vs HK$37.3M). Take a closer look at TradeGo FinTech's potential here in our financial health report. Examine TradeGo FinTech's past performance report to understand how it has performed in prior years. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Jiaze Renewables Corporation Limited focuses on the development, construction, sale, operation, and maintenance of new energy projects and has a market cap of CN¥9.06 billion. Operations: The company's revenue is primarily generated from its operations in China, amounting to CN¥2.49 billion. Market Cap: CN¥9.06B Jiaze Renewables, with a market cap of CN¥9.06 billion, reported Q1 2025 revenue of CN¥660.7 million and net income of CN¥239.62 million, reflecting growth compared to the previous year. The company has strong interest coverage with EBIT seven times its interest payments and well-covered debt by operating cash flow at 35%. However, it faces challenges with high net debt to equity at 70.7% and short-term assets not covering long-term liabilities (CN¥4.3B vs CN¥13.1B). Despite stable weekly volatility and experienced management, Jiaze's profit margins have declined from last year's levels. Unlock comprehensive insights into our analysis of Jiaze Renewables stock in this financial health report. Gain insights into Jiaze Renewables' future direction by reviewing our growth report. Explore the 983 names from our Asian Penny Stocks screener here. Contemplating Other Strategies? Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 25 best rare earth metal stocks of the very few that mine this essential strategic resource. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:2429 SEHK:8017 and SHSE:601619. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
